The situation becomes more complicated in case of target antigens expressed on Treg lymphocytes (anti-CTLA-4) or on tumor cells (anti-PD-L1, anti-CD47), where it could be of high interest to have IgG equipped with effector functions and possibly boosted IgG1 to kill the cells expressing the targeted antigen. Here, CD47 is linked to neoplasm.